Compare Abeona Therapeutics Inc (ABEO) vs IAC/Interactivecorp (PPLI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs IAC/Interactivecorp — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while IAC/Interactivecorp trades at $47.38 (market cap $3.54B). The key difference: IAC/Interactivecorp is far larger — about 9.5× Abeona Therapeutics Inc's market cap, and IAC/Interactivecorp is trading nearer its 52-week high, Abeona Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | PPLI | |
|---|---|---|
Market Cap | $373.32M | $3.54B |
Sector | Health | Media |
52-Week High | $7.23 | $47.62 |
52-Week Low | $4.17 | $31.52 |
Enterprise Value | $228.22M | $3.85B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
PPLI trades at $47.62, up 1.86% today, showing bullish technical momentum with moving averages supporting the uptrend. However, the stock has missed earnings expectations for three consecutive quarters, with Q1 2026 EPS of -$0.94 falling short of the -$0.37 estimate. Despite a high gross margin of 66.49%, net income margin remains thin at 1.75%, and cash flow turned negative in 2025 with a net outflow of $820.42 million. Analyst consensus remains positive with a $55.40 price target, though recent news questions valuation after a rally.
The outlook is mixed: strong analyst buy ratings and a discounted P/B of 0.77 suggest upside potential, but persistent earnings misses and negative cash flow pose significant risks. Revenue decline from $5.2B in 2022 to $2.4B in 2025 highlights operational challenges. Investors should weigh the bullish technical setup against fundamental weaknesses and high debt levels before committing capital.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About IAC/Interactivecorp
IAC Inc is an Internet media company with segments that include Angi (47% of total revenue), Dotdash (10%), search (24%), and emerging and other (19%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.
Read more on PPLI →
